Superior vena cava syndrome

Still a medical dilemma

Pragnyadipta Mishra, Rajini Kausalya

Research output: Contribution to journalArticle

Abstract

Purpose The purpose of this report is to highlight the dilemma and the associated clinical implications in treating a patient with superior vena cava syndrome (SVCS) with a coexisting coagulophathy. Clinical Features: This case report describes a post-bone marrow transplant patient who was admitted to our ICU because of bronchiectasis complicated with nosocomial pneumonia. Following the recovery from pneumonia and long ventilatory support, he developed superior vena cava syndrome (SVCS) due to mediastinal lymphadenopathy. The diagnosis was delayed due to associated confounding clinical factors. Due to the rapid deterioration in patient's condition, the immediate tissue diagnosis of mediastinal lymph nodes and re-canalization of superior vena cava by stenting was not done though it was, our priority. He had many other medical problems as well such as thrombocytopenia, deranged coagulation profile, old cerebral infarction with hemiplegia, seizure disorder and cardiac arrhythmias that complicated the treatment plan. Ultrasonography (USG) guided biopsy followed by stenting of the SVC was done after discussing the risks and benefits with patient's relatives. But, he had bleeding from biopsy site due to deranged coagulation profile. He was not given any anticoagulants. Within 24 hours, the stent was blocked by clot that was diagnosed by the deteriorating clinical features and a repeat CT scan. Then he was given Enoxaparin in therapeutic dose and the clot cleared within a day, possibly partly due to Enoxaparin and partly coagulopathy. Conclusion: Meticulous care should be practiced in deciding the appropriate treatment of SVCS especially when it is associated with other complicating medical problems particularly coagulopathy.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalMiddle East Journal of Anesthesiology
Volume20
Issue number1
Publication statusPublished - Jun 2009

Fingerprint

Superior Vena Cava Syndrome
Enoxaparin
Pneumonia
Biopsy
Superior Vena Cava
Hemiplegia
Bronchiectasis
Delayed Diagnosis
Cerebral Infarction
Thrombocytopenia
Anticoagulants
Stents
Cardiac Arrhythmias
Epilepsy
Ultrasonography
Therapeutics
Lymph Nodes
Bone Marrow
Hemorrhage
Transplants

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Superior vena cava syndrome : Still a medical dilemma. / Mishra, Pragnyadipta; Kausalya, Rajini.

In: Middle East Journal of Anesthesiology, Vol. 20, No. 1, 06.2009, p. 115-120.

Research output: Contribution to journalArticle

@article{98df574af6a74a5a846c0ca3c110ba93,
title = "Superior vena cava syndrome: Still a medical dilemma",
abstract = "Purpose The purpose of this report is to highlight the dilemma and the associated clinical implications in treating a patient with superior vena cava syndrome (SVCS) with a coexisting coagulophathy. Clinical Features: This case report describes a post-bone marrow transplant patient who was admitted to our ICU because of bronchiectasis complicated with nosocomial pneumonia. Following the recovery from pneumonia and long ventilatory support, he developed superior vena cava syndrome (SVCS) due to mediastinal lymphadenopathy. The diagnosis was delayed due to associated confounding clinical factors. Due to the rapid deterioration in patient's condition, the immediate tissue diagnosis of mediastinal lymph nodes and re-canalization of superior vena cava by stenting was not done though it was, our priority. He had many other medical problems as well such as thrombocytopenia, deranged coagulation profile, old cerebral infarction with hemiplegia, seizure disorder and cardiac arrhythmias that complicated the treatment plan. Ultrasonography (USG) guided biopsy followed by stenting of the SVC was done after discussing the risks and benefits with patient's relatives. But, he had bleeding from biopsy site due to deranged coagulation profile. He was not given any anticoagulants. Within 24 hours, the stent was blocked by clot that was diagnosed by the deteriorating clinical features and a repeat CT scan. Then he was given Enoxaparin in therapeutic dose and the clot cleared within a day, possibly partly due to Enoxaparin and partly coagulopathy. Conclusion: Meticulous care should be practiced in deciding the appropriate treatment of SVCS especially when it is associated with other complicating medical problems particularly coagulopathy.",
author = "Pragnyadipta Mishra and Rajini Kausalya",
year = "2009",
month = "6",
language = "English",
volume = "20",
pages = "115--120",
journal = "Middle East Journal of Anesthesiology",
issn = "0544-0440",
publisher = "American University of Beirut",
number = "1",

}

TY - JOUR

T1 - Superior vena cava syndrome

T2 - Still a medical dilemma

AU - Mishra, Pragnyadipta

AU - Kausalya, Rajini

PY - 2009/6

Y1 - 2009/6

N2 - Purpose The purpose of this report is to highlight the dilemma and the associated clinical implications in treating a patient with superior vena cava syndrome (SVCS) with a coexisting coagulophathy. Clinical Features: This case report describes a post-bone marrow transplant patient who was admitted to our ICU because of bronchiectasis complicated with nosocomial pneumonia. Following the recovery from pneumonia and long ventilatory support, he developed superior vena cava syndrome (SVCS) due to mediastinal lymphadenopathy. The diagnosis was delayed due to associated confounding clinical factors. Due to the rapid deterioration in patient's condition, the immediate tissue diagnosis of mediastinal lymph nodes and re-canalization of superior vena cava by stenting was not done though it was, our priority. He had many other medical problems as well such as thrombocytopenia, deranged coagulation profile, old cerebral infarction with hemiplegia, seizure disorder and cardiac arrhythmias that complicated the treatment plan. Ultrasonography (USG) guided biopsy followed by stenting of the SVC was done after discussing the risks and benefits with patient's relatives. But, he had bleeding from biopsy site due to deranged coagulation profile. He was not given any anticoagulants. Within 24 hours, the stent was blocked by clot that was diagnosed by the deteriorating clinical features and a repeat CT scan. Then he was given Enoxaparin in therapeutic dose and the clot cleared within a day, possibly partly due to Enoxaparin and partly coagulopathy. Conclusion: Meticulous care should be practiced in deciding the appropriate treatment of SVCS especially when it is associated with other complicating medical problems particularly coagulopathy.

AB - Purpose The purpose of this report is to highlight the dilemma and the associated clinical implications in treating a patient with superior vena cava syndrome (SVCS) with a coexisting coagulophathy. Clinical Features: This case report describes a post-bone marrow transplant patient who was admitted to our ICU because of bronchiectasis complicated with nosocomial pneumonia. Following the recovery from pneumonia and long ventilatory support, he developed superior vena cava syndrome (SVCS) due to mediastinal lymphadenopathy. The diagnosis was delayed due to associated confounding clinical factors. Due to the rapid deterioration in patient's condition, the immediate tissue diagnosis of mediastinal lymph nodes and re-canalization of superior vena cava by stenting was not done though it was, our priority. He had many other medical problems as well such as thrombocytopenia, deranged coagulation profile, old cerebral infarction with hemiplegia, seizure disorder and cardiac arrhythmias that complicated the treatment plan. Ultrasonography (USG) guided biopsy followed by stenting of the SVC was done after discussing the risks and benefits with patient's relatives. But, he had bleeding from biopsy site due to deranged coagulation profile. He was not given any anticoagulants. Within 24 hours, the stent was blocked by clot that was diagnosed by the deteriorating clinical features and a repeat CT scan. Then he was given Enoxaparin in therapeutic dose and the clot cleared within a day, possibly partly due to Enoxaparin and partly coagulopathy. Conclusion: Meticulous care should be practiced in deciding the appropriate treatment of SVCS especially when it is associated with other complicating medical problems particularly coagulopathy.

UR - http://www.scopus.com/inward/record.url?scp=63849154115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849154115&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 115

EP - 120

JO - Middle East Journal of Anesthesiology

JF - Middle East Journal of Anesthesiology

SN - 0544-0440

IS - 1

ER -